# Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects

> **NCT05152420** · PHASE1 · COMPLETED · sponsor: **VarmX B.V.** · enrollment: 105 (actual)

## Conditions studied

- Coagulation Disorder

## Interventions

- **DRUG:** VMX-C001
- **DRUG:** Placebo
- **DRUG:** Apixaban
- **DRUG:** Rivaroxaban
- **DRUG:** Edoxaban

## Key facts

- **NCT ID:** NCT05152420
- **Lead sponsor:** VarmX B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-29
- **Primary completion:** 2023-02-03
- **Final completion:** 2023-02-03
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2023-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05152420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05152420, "Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05152420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*